Halozyme Therapeutics (HALO) said Wednesday it now expects 2025 preliminary total revenue in the range of $1.39 billion to $1.40 billion, up from its prior range of $1.30 billion to $1.38 billion.

Analysts polled by FactSet expect $1.34 billion.

The biopharmaceutical company said it now expects 2026 non-GAAP earnings in the range of $7.75 to $8.25 per diluted share, up from its previous range of $6.50 to $7. Analysts polled by FactSet expect $8.22.

Total revenue for the year is now expected in the range of $1.71 billion to $1.81 billion, up from its prior outlook of $1.43 billion to $1.53 billion. Analysts surveyed by FactSet expect $1.69 billion.